Expression of Interest

Contact Person/Scientist in Charge

  • Name and surname: Enrique de Álava Casado
  • Email: enrique.alava.sspaSPAMFILTER@juntadeandalucia.es

INSTITUTO DE BIOMEDICINA DE SEVILLA

Department / Institute / Centre

  • Name: Molecular Pathology of Sarcomas and other tumors, Institute of Biomedicine of Seville (IBiS)
  • Address: Avda. Manuel Siurot s/n. IBiS Building Virgen del Rocío University Hospital. 41013, Seville
  • Province: Sevilla

Research Area

  • Life Sciences (LIF)

Brief description of the institution:

The Institute of Biomedicine of Seville is a high quality joint research centre established in 2006 as a health research, being participated by the Andalusian Regional Ministry for Innovation, Science and Enterprise, the Andalusian Regional Ministry of Health, the Spanish National Research Council, the University of Seville and the Andalusian Health Service, having these entities a common interest in fostering collaboration and cooperation and in joining efforts in the field of health research. It is one of the 18 health research institutes accredited in Spain by the Spanish Research Council (Instituto de Salud Carlos III).
IBIS is a multidisciplinary biomedical research centre, with the aim to undertake high quality and competitive research at international level on the most prevalent diseases. IBIS is based on fundamental research at the molecular and cellular level with a view to promote the rapid transfer of knowledge to the clinical setting, at the same time improving the quality of clinical and epidemiological research. It is focused on most prevalent diseases and organized in 4 research areas: Neurosciences, Cardiovascular & Respiratory pathology, Oncohematology & Genetics, and Infectious diseases & Immune system.

Brief description of the Centre/Research Group (including URL if applicable):

Ewing Sarcoma (ES) is a malignant bone and soft-tissue tumor mainly affecting children and young adults. Advances in terms of multimodal therapies in patients presenting localized disease, lead to a surprising overall survival of 70% at 5-year diagnostic. Despite this, patients presenting multifocal/metastatic or refractory disease present disappointing overall survival rates of around 20%.

From a molecular point of view, ES is characterized by the presence of reciprocal chromosomal translocations, giving rise to fusion genes which in turn are translated into chimerical proteins (mostly involving EWSR1-ETS members). These functional chimerical proteins represent the major oncogenic event in ES. They typically involve the EWSR1 gene and a member of the ETS family, mostly FLI1, in about 85% of the cases. This aberrant transcription factor deregulates the transcription of target genes such as IGF1/IGF1R related genes, among many others.

 Despite the evident role of the ES fusion protein, recent evidence has demonstrated that other secondary alterations also play an enormous part in terms of tumor development, progression and even clinical prognostic.

The main research line of our group is based on the definition and characterization of these secondary alterations and how they may affect ES biology. Our goal is to establish new therapeutic targets as well as biomarkers of response to treatment based on preclinical studies focused on alternative/novel therapies.

Project description:

The selected candidate will be involved in Discovery, functional validation and further clinical translation of new therapeutic targets from genomic, integrative proteomic studies in Ewing Sarcoma. Projects ongoing in the lab include:

  • A prospective multicentre study in which we aim to demonstrate through CGH arrays the prognostic value of the gain of chromosome long arm (1qG) and to design and develop diagnostic tools which will allow the selection of patients for specific treatments, with emphasis to FISH and molecular signatures related with the over expression of 1q located genes.
  • Studies focused on possible drug combinations of PARP inhibitors and other DNA-related agents in in vitro and in vivo models in Ewing Sarcoma.
  • Studies with a dual inhibitor of IGF1R/IR in Ewing Sarcoma cell lines, Linsitinib, with a DNA damage inducing agent, Trabectedin, with high levels of synergism.
  • Development of epigenetic studies based in the activity of the chimerical protein EWSR1/FLI1 in models of inducible ectopic expression. These studies include chromatin remodeling, non-coding RNAs and pre-clinical in vitro and in vivo studies with epigenetic-based drugs.
  • Finally, we plan to further study the targets found through in vivo and in vitro studies and according to their effectiveness applied them to future clinical trials in Ewing Sarcoma patients

https://www.ibis-sevilla.es/investigacion/oncohematologia-y-genetica/patologia-molecular-de-los-sarcomas-y-otros-tumores.aspx?lang=en-US

Applications

CV, including contact information of two researchers familiar with the candidate.

Expertise in soft-tissue tumors will be considered positively.

A letter of motivation

Deadline: 31/08/2017

I want to contact the Institution

De acuerdo a lo establecido en el artículo 5 de la Ley Orgánica 15/1999, de 13 de diciembre, de Protección de Datos de Carácter Personal, queremos informarle que sus datos serán incluidos en un fichero del que es titular la Fundación Española para la Ciencia y la Tecnología, y que tiene por finalidad la gestión de servicios de FECYT a la comunidad científica y tecnológica y a la sociedad. Si usted aporta datos de carácter personal de terceros, se compromete a solicitarles su consentimiento inequívoco para ello, de conformidad con lo dispuesto en el artículo 6 de la LOPD.

En el caso en el que acepte ser informado de otras actividades, novedades, productos o servicios relacionados con FECYT queremos informarle que sus datos serán incluidos en un fichero del que es titular la Fundación Española para la Ciencia y la Tecnología, y que tiene por finalidad realizar comunicaciones de carácter institucional general y control documental.

Asimismo, se le informa que puede ejercitar sus derechos de acceso, rectificación, cancelación y oposición en los términos descritos en la L.O.P.D., dirigiéndose a la sede de la Fundación Española para la Ciencia y la Tecnología, sita en C/ Pintor Velázquez nº 5 - Edificio Museo Nacional de Ciencia y Tecnología, 28100 Alcobendas (Madrid).

Compartir en:
  • compartir en twitter
  • compartir en linkedin
  • compartir en facebook
  • compartir en google +